price month
ep line caveat maintain estim
adj ep ahead consensu abax ep
exclud one-tim non-cash tax charg million match
estim line revenu off-set weaker profit factor
line name lower tax rate interest expens ad
ep estim remain target price stand
monument chang model
vet buoy stock profit deterior revenu growth
ex fx rel consist jan pre-announce
estimate slightli plan vetscan placement
plan vet rotor sale vs estimate increas rotor
volum easi comp exclud distributor stock ahead
shift distribut strategi human medic well
plan stronger expect piccolo sale gross margin fell
bp oper expens rose bp anticip invest
sale forc result ebit margin deterior bp
bp view reserv remain strong million
share ebb line result abax share ytd
vs view share move lower rel
opportun caveat quarter includ stock vet
rotor ahead distribut strategi shift declin core vetscan
placement america meaning weaker profit
encourag upcom launch three new product vmx feb
await greater evid traction new salesforc initi
view take time share trade ep
materi premium peer maintain under-perform rate
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
abax lead manufactur point-of-car diagnost
equip particip anim human health care
set develop portabl blood instrument rapidli measur
blood constitu clinician offic set
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
gain veterinari substanti acceler human medic
placement significantli improv relationship vendor
partner rapid traction/launch new pipelin
grey sky valuat assum increasingli
continu difficulti distribut relationship meaning
contribut new product launch unexpect weak
broader industri demand
 close
ep report larg non-ev follow recent pre-announce
focu increment segment disclosur veterinari segment consum
vs estimate instrument sale vs estimate help distributor
stock ahead price increas result abax shift hybrid direct sale
model dynam appar rebound veterinari consum rotor sale
heel growth manag note stock ad
roughli american vet rotor sale vetscan instrument placement fell
yoy intern america american competit placement also
fell yoy unit medic sale impress plan increas
vs estimate albeit notabl easi comp strength piccolo
sale rotor volum
profit deterior higher rotor cost unfavor hematolog sale mix slightli
higher instrument manufactur cost lower asp hematolog instrument well
step invest sale forc expans spend ebit
margin declin bp yoy bp view
abax debut three new product upcom industri confer vmx new
rapid assay urin sediment analyz well upgrad i-stat
hematolog analyz conjunct abbott new recent approv
usda later flow test use detect heartworm diseas lyme
diseas ehrlichiosi anaplasmosi canin util blood serum plasma
sampl compet directli competitor snap
estim million market urin sediment analyz compet
flagship sedivu
relev data point quarter summar
competit account
competit account
veterinari revenu
veterinari sale increas estim core chemistri
vetscan placement deterior vs estimate includ declin
american placement percentag american vetscan placement
competit account tick higher total unit place
consum disc util plan help
aforement distributor stock ahead price increas easi annual
posit note traction rapid assay test build segment growth rise
consist survey work abax heartworm test highest
volum test base averag weekli util particularli vulner rapid
assay categori competitor move direct distribut clearli open
channel abax other offer opportun captur increment market share
longer term motiv help suppli chain note abax rapid assay
continu go distribut current econom
vetscan instrument placement unit
human medic revenu
human medic revenu growth plan albeit notabl easi
comp strength piccolo sale rotor volum human medic
retail opportun remain somewhat elus substant updat on-going
pilot program still repres sizeabl opportun view note abax
contract partner abbott exclus distribut partner piccolo unit
state china automat renew current econom
compani note expect renegoti longer term contract year
latest result better initi expect continu question
abax market share stabil long term retent rate underli consum
util ytd continu track well industri trend view
competit across dognost space subsid consist industri
survey work suggest potenti upsid ahead ep report
next week feb howev abax make dilig effort catch
innov standpoint demonstr step invest
salesforc remain cautiou share lofti ep despit
slow earn growth histor moment growth compani
earn outlook valuat
earn forecast call revenu increas million slower
histor run rate face heighten competit pressur diminish
contribut new distribut partner forecast ep declin
bp ebitda margin deterior given aforement
step invest sale forc expans spend
forecast ep growth revenu growth
million continu challeng competit environ forecast
approxim bp ebitda margin expans
abax share current trade ep premium peer group
anim health compani suggest upsid potenti stock may limit
pt impli multipl ep estim ev/ebitda multipl
discount histor averag multipl respect
better reflect slow growth trajectori
good sold
sell gener admininstr
depreci amort
good sold
sell gener admininistr
depreci amort
compani mention price
